Last updated: October 30, 2026
CYFENDUS is a government-focused anthrax vaccine developed and manufactured by Emergent BioSolutions Inc. The FDA approved CYFENDUS on June 14, 2023, for post-exposure prophylaxis of anthrax disease in adults ages 18 through 65 when alternative recommended vaccines are unavailable or not appropriate.[1] Its commercial value depends primarily on U.S. government procurement, strategic stockpile replenishment, biodefense policy, and manufacturing readiness rather than routine retail vaccination.
Emergent has not publicly reported a standalone CYFENDUS revenue line. Public filings report broader product sales and government-contract activity, so CYFENDUS revenue, gross margin, backlog, and contribution to enterprise earnings cannot be isolated reliably from disclosed financial statements.[2]
What is CYFENDUS and how does it differ from BioThrax?
CYFENDUS is an anthrax vaccine adsorbed with an adjuvant designed to provide post-exposure protection through a two-dose schedule. BioThrax, also known as Anthrax Vaccine Adsorbed, is Emergent's earlier anthrax vaccine and has been used for pre-exposure and post-exposure prophylaxis in defined populations.
| Attribute |
CYFENDUS |
BioThrax |
| Manufacturer |
Emergent BioSolutions |
Emergent BioSolutions |
| Active vaccine platform |
Anthrax Vaccine Adsorbed |
Anthrax Vaccine Adsorbed |
| Adjuvant |
CpG 7909 |
No CpG 7909 adjuvant |
| FDA approval |
June 14, 2023 |
Earlier FDA approval |
| Primary approved use |
Post-exposure prophylaxis in adults 18-65 when alternatives are unavailable or unsuitable |
Pre-exposure and post-exposure use under specified conditions |
| Schedule |
Two doses, one month apart |
Multi-dose schedule depending on indication |
| Commercial channel |
Government and biodefense procurement |
Government, military, occupational and specialized markets |
| Retail market |
Limited |
Limited |
CYFENDUS is not a conventional commercial biologic sold through pharmacies or hospitals. It is a stockpile and emergency-response product. Demand is therefore episodic, contract-driven and linked to national preparedness requirements.
What is the FDA regulatory status of CYFENDUS?
The FDA approved CYFENDUS under the regulatory framework applicable to anthrax countermeasures. The product’s clinical development relies substantially on immunogenicity and animal-model data because controlled human efficacy trials after anthrax exposure are not feasible.[1]
The approved indication is narrow. CYFENDUS is intended for adults 18 through 65 after suspected or confirmed exposure to Bacillus anthracis, when alternative recommended vaccines are not available or not appropriate. It is used with recommended antibacterial drugs as part of post-exposure management.[1]
The regulatory profile creates both commercial protection and market limits:
- The FDA label supports government procurement for emergency response and stockpiling.
- The indication does not create a broad civilian vaccination market.
- Use is concentrated in public-health agencies, military programs, emergency responders and national stockpiles.
- Product demand depends on government policy and inventory planning rather than disease prevalence.
CYFENDUS does not have the market characteristics of a standard preventive vaccine such as influenza, pneumococcal or shingles vaccines. Its addressable population is defined by exposure risk and preparedness requirements.
What patents protect CYFENDUS?
Publicly available regulatory materials identify CYFENDUS as an anthrax vaccine adsorbed product using CpG 7909 as an adjuvant. The commercial protection strategy is likely to involve a combination of formulation, adjuvant-use, manufacturing, process and composition claims rather than a single broad molecule patent.[1]
A complete patent-term analysis requires matching the FDA-approved product to:
- U.S. composition-of-matter patents covering the vaccine-adjuvant combination.
- Formulation patents covering CpG 7909 with anthrax protective antigen.
- Method-of-use patents covering post-exposure prophylaxis.
- Manufacturing patents covering antigen production, purification, adsorption and filling.
- Regulatory exclusivity and government-contract rights.
- Foreign patents relevant to export or non-U.S. government procurement.
No widely reported Orange Book patent listing establishes a conventional small-molecule-style patent expiry framework for CYFENDUS. FDA vaccine products may not present the same Orange Book listing pattern as orally administered generic drugs, and government procurement can remain commercially relevant after core patent expiry where manufacturing know-how, facility qualification and stockpile contracts create practical barriers.
Are CYFENDUS patents listed in the Orange Book?
CYFENDUS does not have the typical Orange Book commercial profile associated with a branded prescription drug facing Abbreviated New Drug Application, or ANDA, substitution. Public FDA materials identify the product and its approval but do not establish a conventional Orange Book-driven generic-entry timetable comparable with products such as Humira, Eliquis or Revlimid.[1,3]
The absence of a clear Orange Book pathway reduces the relevance of standard Paragraph IV litigation analysis. Potential competition is more likely to involve:
- A competing anthrax vaccine.
- A government procurement challenge.
- A biosimilar or follow-on biologic pathway, if applicable.
- A contract manufacturer or defense supplier developing an alternative product.
- A government-funded countermeasure program.
When does CYFENDUS lose exclusivity?
CYFENDUS has no publicly established single loss-of-exclusivity date that can be used as a reliable generic-entry marker. Its effective exclusivity is shaped by regulatory approval, patents, manufacturing qualification and government procurement.
| Protection or barrier |
Commercial effect |
| Product patents |
May restrict copying of the formulation, adjuvant combination or manufacturing process |
| Regulatory approval |
Requires a competing sponsor to establish an acceptable regulatory pathway |
| Manufacturing controls |
Anthrax vaccine production requires specialized facilities, validation and quality systems |
| Government contracts |
Can secure volume commitments and preferred-supplier status |
| Stockpile qualification |
Government purchasers may prioritize validated suppliers over low-cost entrants |
| Emergency preparedness policy |
Can sustain demand after nominal patent expiry |
A competitor could face a longer practical development timeline than a conventional generic drug because technical comparability, lot consistency, adjuvant performance and facility qualification matter as much as patent clearance.
How large is the CYFENDUS market?
The market is strategically important but financially narrow. CYFENDUS is aimed at government buyers rather than a broad population of private patients. The principal demand pools are:
- The U.S. Strategic National Stockpile.
- The Department of Defense.
- The Department of Health and Human Services.
- BARDA procurement programs.
- State and local public-health agencies.
- Emergency-response organizations.
- Selected international biodefense programs.
The addressable market is difficult to quantify because stockpile requirements are classified or disclosed only through contract announcements, budget documents and company filings. Procurement is usually lumpy. A single multiyear contract can produce substantial revenue in one period, followed by lower sales during inventory-maintenance years.
What drives CYFENDUS demand?
CYFENDUS demand is driven by five factors.
First, the government must maintain sufficient anthrax countermeasure inventory. Anthrax remains a recognized biological threat because Bacillus anthracis spores can persist in the environment and can be used in deliberate-release scenarios.
Second, government agencies may diversify suppliers or vaccine technologies. A newer two-dose product can support stockpile flexibility where authorities want alternatives to older vaccination regimens.
Third, product shelf life and inventory rotation create recurring procurement opportunities. Stockpiled medical countermeasures expire and require replacement or replenishment.
Fourth, geopolitical risk and biodefense appropriations can accelerate purchasing. Funding decisions are policy-driven and may not track ordinary healthcare utilization.
Fifth, emergency-use planning can generate option value. Governments may buy capacity and inventory even when there is no current outbreak.
What is the financial trajectory for CYFENDUS?
CYFENDUS is likely to produce a front-loaded and contract-dependent financial trajectory rather than a smooth annual revenue curve.
Launch phase: 2023-2024
The FDA approval created the regulatory basis for government procurement. Early commercial activity would be expected to include launch inventory, qualification, government contracting, manufacturing readiness and possible stockpile purchases.
Emergent’s company-wide financial results during this period cannot be treated as CYFENDUS-specific. The company reports multiple government and commercial products, and its earnings are affected by COVID-19 products, medical countermeasures, contract timing, manufacturing charges and financing conditions.[2]
Expansion phase: 2025-2027
The most important value driver is conversion of regulatory approval into recurring or multiyear procurement. Revenue could rise materially if CYFENDUS is selected for large stockpile purchases or replaces part of an existing anthrax-vaccine inventory.
The financial trajectory would be stronger if Emergent secures:
- Multiyear advance-purchase agreements.
- Minimum-volume commitments.
- Stockpile replenishment orders.
- International government sales.
- Procurement linked to expanded post-exposure protocols.
- Higher-margin supply arrangements based on validated manufacturing capacity.
Mature phase: 2028 and later
At maturity, sales are likely to fluctuate with stockpile rotation, contract renewals and national preparedness budgets. A mature commercial profile could include baseline maintenance orders combined with occasional large replenishment contracts.
CYFENDUS revenue should therefore be modeled using contract scenarios rather than a standard patient-volume forecast.
| Scenario |
Revenue pattern |
Main trigger |
| Downside |
Small, irregular orders |
Limited government adoption and reliance on existing anthrax-vaccine inventory |
| Base case |
Periodic stockpile replenishment |
Recurring U.S. procurement with modest international activity |
| Upside |
Large multiyear awards |
CYFENDUS becomes a preferred alternative for national stockpiles |
| Strategic upside |
Capacity reservation plus inventory sales |
Government purchases manufacturing readiness and product supply |
How much revenue exposure does CYFENDUS create for Emergent?
CYFENDUS creates strategic revenue exposure but not necessarily large recurring pharmaceutical revenue. The product can improve Emergent’s position in government biodefense procurement, yet the company’s financial exposure is determined by contract awards rather than prescription volume.
The key financial variables are:
- Contract value and duration.
- Number of doses ordered.
- Manufacturing yield.
- Cost of CpG 7909 and other raw materials.
- Facility utilization.
- Batch release timing.
- Government payment schedules.
- Product shelf life.
- Inventory write-down risk.
- Dependence on a small number of government buyers.
A large purchase order can produce strong quarterly revenue but may not indicate sustainable annual demand. Investors should distinguish reported product revenue from backlog, committed government funding and nonbinding procurement announcements.
Which companies are challenging CYFENDUS?
No broad retail generic market is currently associated with CYFENDUS. Competitive risk is more likely to come from other anthrax countermeasure developers and incumbent anthrax vaccine suppliers.
The principal competitive reference products are:
| Product or platform |
Sponsor or manufacturer |
Competitive relevance |
| CYFENDUS |
Emergent BioSolutions |
Two-dose post-exposure vaccine with CpG 7909 adjuvant |
| BioThrax |
Emergent BioSolutions |
Established anthrax-vaccine platform and potential internal substitute |
| Anthrax Vaccine Adsorbed programs |
Government and defense suppliers |
Potential procurement alternatives |
| Next-generation anthrax vaccines |
Various developers |
Could compete for stockpile and military contracts |
The most immediate competitive threat may be internal product substitution between CYFENDUS and BioThrax rather than a conventional generic launch. Government agencies could use CYFENDUS for selected scenarios while retaining BioThrax for established programs.
What generic entry risks exist for CYFENDUS?
Generic entry risk is low in the conventional ANDA sense but not zero in the broader competitive sense.
Patent risk
A competing sponsor could challenge formulation, adjuvant or method-of-use patents. The absence of a widely visible Orange Book litigation framework makes a classic Paragraph IV strategy less central.
Regulatory risk
A competitor would need to establish an acceptable regulatory route for an anthrax vaccine. The Animal Rule and immunogenicity-based development framework can reduce the feasibility of direct substitution without substantial nonclinical, clinical and manufacturing evidence.
Manufacturing risk
Anthrax vaccine production requires controlled biological manufacturing, validated assays, specialized facilities and regulatory inspection. These requirements can delay entry even where patent claims are narrow or expired.
Procurement risk
Government buyers may not award contracts solely on price. Supply assurance, domestic production, surge capacity, lot history and emergency deployment readiness can determine supplier selection.
What patent litigation affects CYFENDUS?
No major public Paragraph IV litigation or patent settlement involving CYFENDUS has been widely reported. The absence of reported litigation is consistent with the product’s government-centered market and limited conventional generic-substitution pathway.
Future disputes could concern:
- CpG 7909 use in anthrax vaccination.
- Vaccine composition and adsorption.
- Protective-antigen production.
- Dose and schedule claims.
- Manufacturing methods.
- Trade secrets and quality-control processes.
- Government contract awards and procurement protests.
Contract disputes may have greater commercial relevance than Hatch-Waxman litigation because a competitor could seek access to government demand without first pursuing pharmacy-level substitution.
How does CYFENDUS compare with other biodefense products?
CYFENDUS has a different market structure from many biodefense products.
| Category |
CYFENDUS |
Antiviral or antibiotic countermeasure |
| Disease target |
Anthrax |
Viral or bacterial threat depending on product |
| Demand source |
Primarily government stockpile |
Government stockpile and possible civilian use |
| Sales pattern |
Large, irregular procurement events |
May include recurring treatment demand |
| Patient market |
Narrow |
Potentially broader during outbreaks |
| Substitution |
Limited pharmacy substitution |
May include more conventional generic competition |
| Manufacturing barrier |
High |
Varies by product |
| Revenue visibility |
Low without contract disclosure |
Often higher if commercial prescriptions exist |
CYFENDUS has high strategic value per contract but low ordinary-market visibility. Its commercial success depends on becoming embedded in public procurement plans.
What licensing and partnership factors matter?
Publicly disclosed licensing economics specific to CYFENDUS are limited. The key partnership issue is the relationship among Emergent, U.S. government agencies, BARDA, the Department of Defense and stockpile purchasers.
Relevant deal structures may include:
- Government development funding.
- Advance-purchase commitments.
- Cost-sharing arrangements.
- Manufacturing-capacity reservations.
- Technology-transfer agreements.
- International procurement licenses.
- Contract manufacturing or fill-finish arrangements.
The economic value of a partnership depends on whether the agreement guarantees volume or only funds development and capacity. A development award without binding purchase commitments has less direct revenue value than a multiyear procurement contract.
How strong is the CYFENDUS commercial and patent estate?
CYFENDUS has a strong institutional position but a narrow commercial estate.
Strengths
- FDA approval for a differentiated post-exposure use.
- Established Emergent biodefense infrastructure.
- Government buyer relationships.
- Potential schedule advantage from a two-dose regimen.
- High technical barriers to manufacturing.
- Potential role in stockpile diversification.
Limitations
- No broad routine vaccination market.
- High dependence on government appropriations.
- Limited public revenue transparency.
- Potential overlap with BioThrax.
- Procurement concentration.
- Unclear conventional Orange Book exclusivity profile.
- Contract timing and inventory rotation can create earnings volatility.
The product’s strongest protection may be the combination of regulatory qualification, manufacturing capability and government procurement access rather than patent duration alone.
Key Takeaways
- CYFENDUS is Emergent BioSolutions’ FDA-approved anthrax vaccine for post-exposure prophylaxis in adults 18 through 65 when alternatives are unavailable or unsuitable.
- The product uses anthrax vaccine adsorbed with CpG 7909 and is administered as a two-dose series one month apart.
- Its market is government-led, with demand concentrated in stockpiles, military programs, BARDA and emergency preparedness.
- Emergent does not publicly disclose standalone CYFENDUS revenue, margins or backlog.
- Revenue is likely to be episodic and contract-driven, with substantial quarter-to-quarter volatility.
- No single public loss-of-exclusivity date establishes a conventional generic-launch timetable.
- Orange Book and Paragraph IV dynamics are less central than government procurement, manufacturing qualification and biodefense policy.
- The main competitive risk comes from existing anthrax vaccines, new biodefense platforms and government supplier diversification.
- CYFENDUS has strategic value for Emergent but should not be modeled like a mass-market vaccine or chronic-care biologic.
- The most important valuation indicators are multiyear procurement awards, minimum-volume commitments, stockpile replenishment and manufacturing-capacity utilization.
FAQs
Is CYFENDUS a biologic or a vaccine?
CYFENDUS is a biologic vaccine product. It is an anthrax vaccine adsorbed with an adjuvant and is regulated as a biological product by the FDA.
Who manufactures CYFENDUS?
Emergent BioSolutions manufactures CYFENDUS and is the principal commercial sponsor identified in FDA and company materials.
Can pharmacies substitute a generic version of CYFENDUS?
Routine pharmacy substitution is not the principal competitive pathway. CYFENDUS is primarily purchased through government and biodefense channels, where a competing product would need separate regulatory approval and procurement qualification.
Does CYFENDUS compete directly with BioThrax?
Yes. Both are anthrax vaccine products from Emergent, although their formulations, schedules and approved-use profiles differ. CYFENDUS may complement BioThrax or replace it in selected post-exposure settings.
What is the most important investment risk for CYFENDUS?
The primary risk is procurement concentration. A strong FDA label does not guarantee recurring commercial sales because demand depends on government budgets, stockpile strategy, contract awards and replenishment timing.
References
-
U.S. Food and Drug Administration. (2023). CYFENDUS: Anthrax vaccine adsorbed, adjuvanted prescribing information and approval announcement. FDA.
-
Emergent BioSolutions Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
